What is the current vaccination coverage for respiratory syncytial virus among US adults?
Respiratory syncytial virus (RSV) can cause severe illness in older adults. Vaccines for RSV became available in the US in 2023 for adults aged 60 and older. Current coverage among US adults is low, especially compared to flu and COVID-19 vaccines. The best available data comes from nursing home residents, where only about 1 in 10 received the RSV vaccine by late 2023 9.
What the research says
A December 2023 report from the CDC's National Healthcare Safety Network found that among nursing home residents at facilities that voluntarily reported RSV vaccination data, only 9.8% had received an RSV vaccine 9. This was much lower than influenza vaccine coverage (72.0%) and COVID-19 booster coverage (33.1%) in the same population 9. Vaccination rates varied by region, social vulnerability, and facility size 9. Another report on US adult vaccination coverage notes that data on RSV vaccination among eligible adults is still being collected, but early figures suggest low uptake 4. A 2025 review of RSV vaccines states that three vaccines are now approved for adults 60 and older: Arexvy, Abrysvo, and mRESVIA 8. However, the review does not provide specific coverage numbers 8. Overall, the evidence indicates that RSV vaccination coverage among US adults, particularly older adults, remains low in the first season of availability.
What to ask your doctor
- Am I eligible for an RSV vaccine based on my age and health conditions?
- Which RSV vaccine (Arexvy, Abrysvo, or mRESVIA) is recommended for me?
- Can I get the RSV vaccine at the same time as my flu or COVID-19 vaccine?
- How long does protection from the RSV vaccine last, and will I need a booster?
- What are the common side effects of the RSV vaccine?
This question is drawn from common patient questions about Primary Care & Family Medicine and answered using cited medical research. We do not provide individualized advice.